Toceranib is a drug registered for use in dogs for the treatment of mast cell neoplasia. It is an anti-angiogenic and antiproliferative agent that belongs to a class of drugs that inhibits the receptor sites of the enzyme tyrosine kinase (TK). When bound, TKs enhance cell proliferation, among other processes. Mutated TKs are implicated in cell growth and division of tumor cells, hence, blocking of TK enzyme binding sites with Toceranib can be utilized as effective treatment for non-mastocytic cancers, and in particular for neuroendocrine neoplasias of canine and feline patients.